Advertisement

The future of relievers and controllers in asthma therapy

  • Alberto Papi
  • B. Beghé
  • G. Caramori
  • A. Ciaccia
  • L. M. Fabbri
Conference paper

Summary

Treatment of persistent asthma with anti-inflammatory and bronchodilator agents will probably remain in the first line treatment for at least the next 5 years. The only 2 new options that might become available in the next five years are: a) the use of long-acting bronchodilators, and particularly inhaled salmeterol and formoterol, alone or in combination with very low dose inhaled glucocorticoids; and/or b) cysteinyl-leukotrienes receptor-antagonists and synthesis-inhibitors. Also the pharmacologic treatment of asthma exacerbations will not probably change significantly in the near future.

Keywords

Allergy Clin Immunol Respir Crit Asthma Exacerbation Acute Asthma Persistent Asthma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Thoracic Society Committee on Diagnostic Standards for Non tuberculous Respiratory Diseases (1962). Definition and classification of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis 85: 762–768Google Scholar
  2. 2.
    Sheffer AL (ed) Global Initiative for Asthma. NHLBI/WHO Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Publication No. 95–3659. January 1995Google Scholar
  3. 3.
    Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH (1995) Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 152: 45–52PubMedGoogle Scholar
  4. 4.
    Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijarvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen LA (1991) Comparison of a beta,-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 325: 388–392PubMedCrossRefGoogle Scholar
  5. 5.
    Trigg CJ, Manolitsas ND, Wang J, Calderòn MA, McAulay A, Jordan SE, Herdman MJ, Jhalli N, Duddle JM, Hamilton SA, Devalia JL, Davies RJ (1994) Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 150: 17–22.PubMedGoogle Scholar
  6. 6.
    Manolitsas ND, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ (1995) Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am J Respir Crit Care Med 151: 1925–1930PubMedGoogle Scholar
  7. 7.
    Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST (1995) The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 8: 831–833PubMedGoogle Scholar
  8. 8.
    Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J Med 332: 868–875PubMedCrossRefGoogle Scholar
  9. 9.
    Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH (1994) Effects of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 150: 1006–1011PubMedGoogle Scholar
  10. 10.
    Nelson HS (1995) Drug therapy: β-adrenergic bronchodilators. N Engl J Med 333: 499–506PubMedCrossRefGoogle Scholar
  11. 11.
    Finnerty JP, Lee C, Wilson S, Madden J, Djukanovic R, Holgate ST (1996) Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. Eur Respir J 9: 1672–1677PubMedCrossRefGoogle Scholar
  12. 12.
    Sullivan P, Bekir S, Jaffar Z, Page CP, Jeffery P, Costello J (1994) Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343: 1006–1008PubMedCrossRefGoogle Scholar
  13. 13.
    Weinberger M, Hendeles L (1996) Theophylline in asthma. N Engl J Med 334: 1380–1388PubMedCrossRefGoogle Scholar
  14. 14.
    Greening AP, Ind PW, Northfield M, Shaw G, on behalf of Allen and Hanburys Limited UK Study Group (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344: 219–224CrossRefGoogle Scholar
  15. 15.
    Woolcock A, Lundback B, Ringdal OLN, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153: 1481–1488PubMedGoogle Scholar
  16. 16.
    Faurschou P, Steffensen I, Jacques L, European Respiratory Group (1996) Effect of addition of inhaled salmeterol to the moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. Eur Respir J 9: 1885–1890PubMedCrossRefGoogle Scholar
  17. 17.
    Kemp JP, Dockhorn J, Busse WW, Bleecker ER, van As A (1994) Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 150: 1612–1615PubMedGoogle Scholar
  18. 18.
    Karpell JP, Schacter EN, Fanta C, Levey D, Spiro P, Aldric T, Menjoge SS, Witex TJ (1996) A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Chest 110: 611–616CrossRefGoogle Scholar
  19. 19.
    Campbell IA, Colman SB, Mao JH, Prescott RJ, Weston CFM (1995) An open, prospective comparison of beta,-agonists given via nebuliser, Nebuhaler, or pressurised inhaler by ambulance crew as emergency treatment. Thorax 50: 79–80PubMedCrossRefGoogle Scholar
  20. 20.
    Fergusson RI, Stewart CM, Wathen CG, Moffat R, Crompton GK (1995) Effectiveness of nebulised salbutamol administered in ambulances to patients with severe acute asthma. Thorax 50: 81–82PubMedCrossRefGoogle Scholar
  21. 21.
    Idris AH, McDermott MF, Raucci JC, Morrabel A, McGorray S, Hendeles L (1993) Emergency Department treatment of severe asthma: metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 103: 665–672PubMedCrossRefGoogle Scholar
  22. 22.
    Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, Duroux P, Simonneau G (1994) Nebulized versus intravenous albuterol in hypercapnic acute asthma: a multicenter, double-blind, randomized study. Am J Respir Crit Care Med 149: 1466–1470PubMedGoogle Scholar
  23. 23.
    Coleridge J, Cameron P, Epstein J, Teichtahl H (1993) Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. Aust N Z J Med 23: 348–354PubMedCrossRefGoogle Scholar
  24. 24.
    Huang D, O’Brien RG, Harman E, Aull L (1993) Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma. Ann Intern Med 119: 1155–1160PubMedGoogle Scholar
  25. 25.
    Janson C, Boman G, Boe J (1992) Which patients benefit from adding theophylline to beta,-agonist treatment in severe acute asthma?. Ann Allergy 69: 107–110PubMedGoogle Scholar
  26. 26.
    Murphy DG, McDermott MF, Rydman RJ, Sloan EP, Zalenski RJ (1993) Aminophylline in the treatment of acute asthma when beta,-adrenergics agents and steroids are provided. Arch Intern Med 153: 1784–1788PubMedCrossRefGoogle Scholar
  27. 27.
    Rodrigo C, Rodrigo R (1994) Treatment of acute asthma: lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. Chest 106: 1071–1076PubMedCrossRefGoogle Scholar
  28. 28.
    Zainudin BMZ, Ismail O, Yusoff K (1994) Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. Thorax 49: 267–269PubMedCrossRefGoogle Scholar
  29. 29.
    Skorodin MS (1995) Magnesium in pulmonary and critical care medicine. Clin Pulm Med 2: 231–237CrossRefGoogle Scholar
  30. 30.
    Levy ML, Stevenson C, Maslen T (1996) Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 51: 1087–1092PubMedCrossRefGoogle Scholar
  31. 31.
    Lim TK (1996) Comparison of inhaled fluticasone propionate and oral prednisolone in the treatment of acute severe asthma. Am J Respir Care Med 153 [Suppl]: A340Google Scholar
  32. 32.
    Morice AH, Morris D, Lawson-Mattehew (1995) Nebulised budesonide in acute severe asthma. Am J Respir Care Med 151 [Suppl]: A274Google Scholar
  33. 33.
    Praparn Y, Maranetra N, Nana A, Charoenratanakul S, Boe J, Lofdahl C-G, Selroos O, Stahl E (1995) Inhaled as effective as oral steroids after an acute asthma attack. Am J Respir Care Med 151 [Suppl]: A274Google Scholar
  34. 34.
    van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV (1996) Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 9: 1684–1688PubMedCrossRefGoogle Scholar
  35. 35.
    Rebuck AS, Chapman KR, Abboud R, Pare PD, Kreisman H, Wolkove N, Vickerson F (1987) Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 82: 59–64PubMedCrossRefGoogle Scholar
  36. 36.
    O’Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A (1989) Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 2: 1418–1420CrossRefGoogle Scholar
  37. 37.
    Bryant DH (1985) Nebulized ipratropium bromide in the treatment of acute asthma. Chest 88: 24–29PubMedCrossRefGoogle Scholar
  38. 38.
    Higgins RM, Stradling JR, Lane DJ (1988) Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? Chest 94: 718–722PubMedCrossRefGoogle Scholar
  39. 39.
    Leahy BC, Gomm SA, Allen SC (1983) Comparison of nebulised salbutamol with nebulised ipratropium bromide in acute asthma. Br J Dis Chest 77: 159–163PubMedCrossRefGoogle Scholar
  40. 40.
    Summers QA, Tarala RA (1990) Nebulised ipratropium in the treatment of acute asthma. Chest 97: 430–434CrossRefGoogle Scholar
  41. 41.
    Ward MJ, McFarlane JT, Davies D (1985) A place for ipratropium bromide in the treatment of severe acute asthma. Br J Dis Chest 79: 374–378PubMedCrossRefGoogle Scholar
  42. 42.
    Bauer R (1992) The pharmacology of oxitropium bromide. Rev Contemp Pharmocoter 3: 197–203Google Scholar
  43. 43.
    Crane J, Pearce N, Burgess C, Beasley R (1995) Asthma and the 13-agonist debate. Thorax 50 [Suppl 1]: S5 - S10PubMedCrossRefGoogle Scholar
  44. 44.
    Barnes PJ, Pedersen S (1993) Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 148 [Suppl]: S1 - S26PubMedGoogle Scholar
  45. 45.
    Matthys H (1990) Inhalation delivery of asthma drugs. Lung [Suppl]: 645–652CrossRefGoogle Scholar
  46. 46.
    Kelloway JS, Wyatt RA, Adlis SA (1994) Comparison of patients’compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 154: 1349–1352PubMedCrossRefGoogle Scholar
  47. 47.
    Fabbri L, Caramori G, Cosma P, Ciaccia A (1996) Methotrexate in the treatment of systemic glucocorticoid dependent severe persistent astma: a word of caution. Monaldi Archiv Chest Dis 51: 130–137Google Scholar
  48. 48.
    Dahlèn B, Dahlèn S-E (1995) Leukotrienes as mediators of airway obstrution and inflammation in asthma. Clin Exp Allergy 25 [Suppl 2]: 50–54PubMedCrossRefGoogle Scholar
  49. 49.
    Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH (1993) Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341: 989–990PubMedCrossRefGoogle Scholar
  50. 50.
    Stechschulte DJ (1990) Leukotrienes in asthma and allergic rhinitis. N Engl J Med 323: 1769–1770PubMedCrossRefGoogle Scholar
  51. 51.
    Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegal SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM (1993) The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 119: 1059–1066PubMedGoogle Scholar
  52. 52.
    Israel E, Cohn J, Dibè L, Drazen MJ, for the Zileuton Clinical Trial Group (1996) Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized clinical trial. J Am Med Assoc 275: 931–936CrossRefGoogle Scholar
  53. 53.
    Meltzer SS, Hasday JD, Cohn J, Bleecker ER (1996) Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 153: 931–935PubMedGoogle Scholar
  54. 54.
    Spector SL, Smith U, Glass M and the AccolateTM Asthma trialists Group (1994) Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 150: 618–623PubMedGoogle Scholar
  55. 55.
    Kane GC, Pollice M, Kim CJ, Cohn J, Dworski RT, Murray JJ, Sheller JR, Fish JE, Peters SP (1996) A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 97: 646–654PubMedCrossRefGoogle Scholar
  56. 56.
    Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY (1995) Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152: 897–905PubMedGoogle Scholar
  57. 57.
    Ikeda K, Obata H, Fujita H, Nahanishi T, Tsuruta R (1996) Pranlukast (ONO-1078, leukotriene receptor antagonist) enabled to reduce steroid doses in chronic severe adult asthma. Chest 110 [Suppl]: 88s abstractGoogle Scholar
  58. 58.
    Evans DJ, Barnes PJ, Spaethe MS, van Alstyne EL, Mitchell M, O’Connor BJ (1996) Effect of a leukotriene B4 Receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 51: 1178–1184PubMedCrossRefGoogle Scholar
  59. 59.
    Banner KH, Page CP (1995) Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 8: 996–1000PubMedGoogle Scholar
  60. 60.
    Bianco S, Vaghi A, Robuschi M, Refini RM, Pieroni MG, Sestini P (1995) Steroid-sparing effect of inhaled lysine acetylsalicylate and furosemide in high-dose beclomethasone-dependent asthma. J Allergy Clin Immunol 95: 937–943PubMedCrossRefGoogle Scholar
  61. 61.
    Ichinose M, Miura M, Yamauchi H, Kageyama N, Tomaki M, Oyake T, Ohuchi Y, Hida W, Miki H, Tamura G, Shirato K (1996) A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 153: 936–941PubMedGoogle Scholar
  62. 62.
    Regoli D, Boudon A, Fauchère J-L (1994) Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46: 551–599PubMedGoogle Scholar
  63. 63.
    Bertrand C, Geppetti P (1996) Tachykinin and kinin receptor antagonist: therapeutic prospectives in allergic airway disease. Trends Pharmacol Sci 17: 255–259PubMedCrossRefGoogle Scholar
  64. 64.
    Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA (1996) The effect of treatment with a monoclonal antibody directed against IgE on allergic airway response in asthmatic subjects. J Allergy Clin Immunol 97: 358, abstract 702CrossRefGoogle Scholar
  65. 65.
    Cockcroft DW, Kalra S, Bhagat R, Swystum VA, Boulet L-P, Cote J, Laviolette M, Deschesnes F, Chapman KR, Cleland LD, Fick RB, Su J, De Vault A (1996) rhuMAb-E25(E25), humanized murine monoclonal anti-IgE, inhibits the allergen-induced early asthmatic response (EAR). J Allergy Clin Immunol 97: 315, abstract 532CrossRefGoogle Scholar
  66. 66.
    Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM (1995) Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 152: 800–803PubMedGoogle Scholar
  67. 67.
    Lunderberg JON, Weitzberg E, Lunderberg JM, Alving K (1996) Nitric oxide in exhaled air. Eur Respir J 9: 2671–2680CrossRefGoogle Scholar
  68. 68.
    Yates DH, Kharitonov SA, Thomas PS, Barnes PJ (1996) Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. Am J Respir Crit Care Med 154: 247–250PubMedGoogle Scholar
  69. 69.
    Barnes PJ, Liew FY (1995) Nitric oxide and asthmatic inflammation. Immunol Today 16: 128–130PubMedCrossRefGoogle Scholar
  70. 70.
    Kuitert LM, Angus RM, Barnes NC, Barnes PJ, Bone MF, Chung KF, Fairfax AJ, Higenbotham TW, O’Connor BJ, Piotrowska B, Rozniecki J, Uden S, Walters EH, Willard CJ (1995) Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 151: 1331–1335PubMedGoogle Scholar
  71. 71.
    Spencer DPS, Johnston SL, Calverley PMA, Dhillon P, Higging C, Ramhamadany E, Turner S, Winning A, Winter J, Holgate ST (1994) The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am J Respir Crit Care Med 149: 1142–1148Google Scholar
  72. 72.
    Cazzola M, Matera MG, D’Amato G, Rossi F (1995) Effects of serotonin on airways: recent developments. Allergy 50: 1–10PubMedCrossRefGoogle Scholar
  73. 73.
    Faurschou P, Mikkelsen KL, Steffensen I, Franke B (1994) The lack of bronchodilator effect and the short-term safety of cumulative single doses of an inhaled potassium channel opener (bimakalim) in adult patients with mild to moderate bronchial asthma. Pulm Pharmacol 7: 293–297PubMedCrossRefGoogle Scholar
  74. 74.
    Spector S, Miller CJ, Glass M (1995) 13-week dose-response study with accolateTM (zafirlukast) in patients with mild to moderate asthma. Am J Respir Crit Care Med 151 [Suppl]: A379Google Scholar
  75. 75.
    Williams AJ, Lee TH, Cochrane GM, Hopkirk A, vyse T, Chiew F, Lavender E, Richards DH, Owen S, Stone P, Church S, Woodcock AA (1990) Attenuation of nocturnal asthma by cromakalim. Lancet 336: 334–336PubMedCrossRefGoogle Scholar
  76. 76.
    Dahlen S-E (1996) Personal comunication to L. FabbriGoogle Scholar
  77. 77.
    Casale TB, Costa JJ, Galli SJ (1996) TNFa is important in human lung allergic reactions. Am J Respir Cell Mol Biol 15: 35–44PubMedGoogle Scholar
  78. 78.
    Cruikshank WW, Long A, Tarpy RE, Kornfeld H, Caroll M, Teran L, Holgate ST, Center DM (1995) Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein la ( MIPI a) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 13: 738–747PubMedGoogle Scholar
  79. 79.
    Egan RW, Umland SP, Cuss FM, Chapman RW (1996) Biology of interleukin-5 and its relevance to allergic disease. Allergy 51: 71–81PubMedGoogle Scholar
  80. 80.
    Kips JC, Brusselle GJ, Joos GF, Peleman RA, Tavernier JA, Devos RR, Pauwels RA (1996) Interleukin-12 inhibits antigen-induced airway hyper-responsiveness in mice. Am J Respir Crit Care Med 153: 535–539PubMedGoogle Scholar
  81. 81.
    Moller MG, de Jong TAW, van der Kwast TH, Overbeek SE, Wierenga-Wolf AF, Thepen T, Hoogsteden HC (1996) Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol 14: 439–443PubMedGoogle Scholar
  82. 82.
    Robinson DS, Tsicopoulos A, Meng Q, Durham SM, Kay BA, Hamid Q (1996) Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. Am J Respir Cell Mol Biol 14: 113–117PubMedGoogle Scholar
  83. 83.
    Teran LM, Davies DE (1996) The chemokines: their potential role in allergic inflammation. Clin Exp Allergy 26: 1005–1019PubMedCrossRefGoogle Scholar
  84. 84.
    van Oosterhout AJM, Savelkoul HFJ (1995) Interleukin 5 as a drug target in allergy and asthma. Trends Pharmacol Sci 16: 37PubMedCrossRefGoogle Scholar
  85. 85.
    Sandford A, Weir T, Parè P (1996) The genetics of asthma. Am J Respir Crit Care Med 153: 1749–1765PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1998

Authors and Affiliations

  • Alberto Papi
    • 1
  • B. Beghé
    • 1
  • G. Caramori
    • 1
  • A. Ciaccia
    • 1
  • L. M. Fabbri
    • 1
  1. 1.Institute of Respiratory DiseasesUniversity of FerraraItaly

Personalised recommendations